Trials / Recruiting
RecruitingNCT04689152
Clinical Trial to Evaluate the Efficacy and Safety of Cellgram-LC Administration in Patients With Alcoholic Cirrhosis
A Multicenter, Randomized, Open-label Phase III Clinical Trial to Evaluate Efficacy and Safety of the Cellgram-LC in Patients With Alcoholic Liver Cirrhosis
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 200 (estimated)
- Sponsor
- Pharmicell Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years – 71 Years
- Healthy volunteers
- Not accepted
Summary
This phase III clinical trial is designed to evaluate the efficacy and safety of autologous Mesenchymal Stem Cells (MSC) injected hepatic artery.
Detailed description
To evaluate the efficacy and efficacy for 60 months after a single dose of Cellgram-LC in patients with alcoholic liver cirrhosis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Cellgram-LC | Patients will receive single injection of Cellgram-LC(mesenchymal stem cell) hepatic artery. |
Timeline
- Start date
- 2021-03-02
- Primary completion
- 2027-08-02
- Completion
- 2028-01-02
- First posted
- 2020-12-30
- Last updated
- 2024-03-21
Locations
11 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT04689152. Inclusion in this directory is not an endorsement.